PRME — Prime Medicine Income Statement
0.000.00%
Last trade - 00:00- $740.09m
- $526.81m
- $2.98m
Annual income statement for Prime Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.21 | 0 | 0 | 0 | 2.98 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.14 | 84.5 | 117 | 205 | 205 |
| Operating Profit | -0.932 | -84.5 | -117 | -205 | -202 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.54 | -166 | -123 | -198 | -196 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.41 | -165 | -122 | -198 | -196 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.41 | -165 | -122 | -198 | -196 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.05 | -184 | -142 | -198 | -196 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.054 | -1.95 | -1.46 | -2.18 | -1.65 |
| Dividends per Share |